医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Taro to Announce Results for Year Ended March 31, 2017 on May 22, 2017

2017年05月16日 AM07:55
このエントリーをはてなブックマークに追加


 

HAWTHORNE, N.Y.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the fiscal year ended March 31, 2017, on Monday, May 22, 2017.

The Company will conduct an earnings call at 8:00 am EDT on Tuesday, May 23, 2017, where senior management will discuss the Company’s performance and answer questions from participants.

The release will be accessible on Taro’s website at www.taro.com.

Earnings Call (8:00 am EDT on Tuesday, May 23, 2017)

To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.taro.com. A transcript of this earnings call will also be available on the website.

Summary of events

         
Event   Date and time   Telephone number/ website
Earnings release   May 22, 2017 (AMC)  

www.taro.com

Earnings conference call   8:00 am EDT

May 23, 2017

 

Participant Toll-Free Dial-In Number: +1 (844) 421-0601

Participant International Dial-In Number: +1 (716) 247-5800

ID: 21985230

 

Via audio webcast, details of which will be made available on www.taro.com

Replay of conference call   May 23, 2017 to

June 15, 2017

 

+ 1 (855) 859-2056 or +1 (404) 537-3406

ID: 21985230

 

Via audio webcast playback, details of which will be made available on www.taro.com

   

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170515006788/en/

CONTACT

Taro Pharmaceutical Industries Ltd.
Mariano A. Balaguer, (914)
345-9001
VP, CFO
Mariano.Balaguer@taro.com
or
William
J. Coote, (914) 345-9001
AVP, Business Finance, Treasurer
and Investor Relations
William.Coote@taro.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果